相关实验视频
Updated: May 5, 2026
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.2K
在心力衰竭中,Mib2通过Runx2-Hmgcs2轴通过保存的射出分数调节脂质新陈代谢
Zhulan Cai1,2,3,4, Shunyao Xu5, Xiaohua Xiao6
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
Journal of cellular and molecular medicine
|March 31, 2025
概括
头脑炸弹2 (Mib2) 降解了Runx2,抑制了脂肪酸代谢,并使心力衰竭恶化,保留了喷射分数 (HFpEF) 和小鼠的脂质积累.
科学领域:
- 心血管生物学 心血管生物学
- 代谢障碍 代谢障碍 代谢障碍
- 分子机制的分子机制
背景情况:
- 肥胖和脂质障碍是导致心力衰竭的关键因素,其中包括心力衰竭与保存的喷射分数 (HFpEF).
- 在HFpEF中控制代谢变化和脂质失调的精确分子途径尚未完全阐明.
- 了解这些机制对于开发有针对性的疗法至关重要.
研究的目的:
- 研究HFpEF中脂肪代谢失调背后的分子机制.
- 在HFpEF的背景下,确定参与心脏脂质平衡的关键蛋白质和途径.
- 阐明心智炸弹E3在HFpEF病变发生过程中所起的作用.
主要方法:
- 利用了来自HFpEF患者的转录组数据和小鼠模型 (缺素的ob/ob小鼠).
- 通过AAV9-cTNT-Mib2在小鼠中使用心脏特异性的Mib2过度表达.
- 在新生小鼠心室肌细胞上进行了体外脂毒性研究.
- 进行了蛋白质组分析,双化酶记者测定和免疫沉测定.
主要成果:
- 在HFpEF心脏中差异表达的蛋白质在脂肪酸代谢途径中得到丰富.
- 在HFpEF小鼠心脏中观察到3 - 基-3 - 甲基氨基-CoA合成酶2 (Hmgcs2) 的高表达.
- Mib2与Runx2直接相互作用,导致Runx2的无处不在和降解,从而抑制Hmgcs2的转录.
- 心脏特异性Mib2过度表达在HFpEF小鼠中加剧了心脏功能障碍和脂质积累.
结论:
- 在HFpEF中,Mib2在调节心脏脂质代谢平衡中起着至关重要的作用.
- Mib2-Runx2-Hmgcs2轴是涉及HFpEF病理生理学的关键途径.
- 准这一轴可能为管理与代谢功能障碍相关的HFpEF提供治疗潜力.
相关概念视频
02:23Master Transcription Regulators
6.1K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805